OTCBB:CYKN; Cyberkinetics) issued a statement to honor Stephen Heywood, the first participant with advanced ALS (amyotrophic lateral sclerosis, or Lou Gehrig’s disease) to participate in the Cyberkinetics’ BrainGate Neural Interface System (BrainGate) clinical trial. Stephen, 37, died Sunday, November 26, 2006, as the result of respiratory failure that was unrelated to the BrainGate technology. Stephen enrolled in the pilot trial of the BrainGate System in January 2006.
